SenzaGen inks agreement with CRO to expand in vitro testing

By Melissa Fassbender contact

- Last updated on GMT

(Image: Getty/ImageSource)
(Image: Getty/ImageSource)

Related tags: In vitro, Toxicology

In response to a growing interest in alternative testing methods, SenzaGen signs a license agreement with MB Research Labs to expand the use of its animal-free testing platform.

The contract research organization (CRO) MB Research Labs provides good laboratory (GLP) in vitro​ toxicological testing in the US.

SenzaGen’s agreement with the contract research organization (CRO) gives MB Research Labs the right to globally market and sell SenzaGen’s animal-free GARD test platform, which includes a set of allergy tests that are performed in vitro​ in combination with artificial intelligence (AI).

SenzaGen CEO Anki Malmborg Hager said the agreement “also further strengthens SenzaGen’s presence in the US market.”

“There is a keen interest in animal-free and alternative test methods with introductions in legislation of bans on animal testing for cosmetic and other products,” ​Malmborg told us.

According to the company, the US currently accounts for more than one-third of the global market for cell-based in vitro​ testing.

While California is the first state to pass legislation aimed at reducing animal testing, Malmborg said this market is expected to grow as more states face similar bans.

Related news

Show more

Related products

Q2 Solutions: Corporate Brochure

Q2 Solutions: Corporate Brochure

Q2 Solutions | 17-Apr-2020 | Product Brochure

We are an innovative, progressive and responsive partner with the global experience, medical expertise and focus on quality that is integral to drug, medical...

Global Clinical Trial Lab Services

Global Clinical Trial Lab Services

Q2 Solutions | 01-Apr-2020 | Product Presentation

As a leading global lab services partner, we provide operational excellence, scientific leadership and innovation through technology. We offer end-to-end...

Manufacturing Cyto and Non-Cyto Drugs in One Facility

Manufacturing Cyto and Non-Cyto Drugs in One Facility

Baxter BioPharma Solutions | 01-Mar-2020 | Technical / White Paper

Recent market reports suggest increasing product niches, which may lead to decreasing numbers of units per product, making dedicated facilities less practical....

Related suppliers

Follow us

Products

View more

Webinars